This is the authors' abstract. We don't add key points for this paper.
Aim Kaempferol and Myricetin alone have promising benefits on diabetes and related complications, yet the effectiveness of cotreating the two compounds on diabetes have not been studied. The existing investigation was to study the combined anti-diabetic effect of kaempferol and myricetin in streptozotocin (STZ)-activated diabetes in rats. Methods To evaluate the antidiabetic activity, 36 Wistar rats were segregated into six groups; Normal, 50 mg/kg STZ-induced diabetes, and four (50 mg/kg kaempferol, 50 mg/kg myricetin, 25mg/kg kaempferol + myricetin, and 5mg/kg glibenclamide) compound-treated diabetic groups. The effects of co-treatment on parameters, glucose, insulin, lipid profile, liver enzymes, antioxidant biomarkers, and inflammatory cytokines were measured. Results The study revealed that combined treatment restored the assessed parameters including glucose levels, insulin levels, inflammatory cytokines, oxidative markers, and lipid and liver enzymes in diabetic rats. Conclusion The results indicate that cotreatment of kaempferol and myricetin has beneficial role against diabetes suggesting that cotreatment of these compounds can be used therapeutically in treating diabetes.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Al‐Abbasi et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: